Sakitamiwa Classification Portable May 2026

Understanding the Sakita-Miwa Classification for Peptic Ulcers

The Sakita-Miwa classification is a widely recognized endoscopic system used to evaluate the life cycle and healing progress of peptic ulcers, including gastric and duodenal ulcers. By categorizing ulcers into specific stages, clinicians can standardize the assessment of treatment efficacy, monitor healing quality, and predict the risk of complications like rebleeding. The Three Main Stages and Six Substages

The system divides the ulcer life cycle into three primary stages: Active (A), Healing (H), and Scarring (S). Each stage is further divided into two substages (1 and 2) to provide a granular view of the mucosal defect’s status. 1. Active Stage (A)

This stage represents the acute phase of the ulcer where the mucosal defect is most prominent.

A1 (Active-1): The ulcer is deep, and the base is covered with a thick white or yellowish slough (exudate). The surrounding mucosa is typically red and swollen (edematous).

A2 (Active-2): The edema in the surrounding mucosa begins to subside. The ulcer margin becomes sharper and more clearly defined, though the white coating remains thick. 2. Healing Stage (H)

As treatment progresses, the ulcer enters the healing phase, characterized by the gradual reduction of the slough and the appearance of regenerative tissue.

H1 (Healing-1): A thin white coating remains, but regenerating epithelium (new skin-like lining) begins to appear at the ulcer margins, often forming a "palisade" or star-like pattern as it creeps inward. sakitamiwa classification

H2 (Healing-2): The ulcer becomes significantly shallower and smaller. The regenerative epithelium covers a larger portion of the base, and the white coating is markedly reduced. 3. Scarring Stage (S)

This final stage indicates that the ulcer has closed, though the underlying tissue is still maturing.

The Sakita-Miwa classification is a widely recognized endoscopic system used to stage the life cycle and healing process of peptic ulcers . It divides the ulcer's progression into three main stages—Active, Healing, and Scarring—each containing two sub-stages . Sakita-Miwa Classification Guide Key Endoscopic Characteristics Active (A) A1

Thick white coating (slough/exudate) on the ulcer base; sharp, swollen, or edematous margins . A2

Slough becomes thinner; edema at the margin begins to decrease; the ulcer base is clearly demarcated . Healing (H) H1

Regenerating epithelium (reddish area) appears at the ulcer margin; ulcer becomes shallower . H2

Regenerating epithelium covers most of the ulcer base, leaving only a tiny amount of slough in the center . Scarring (S) S1 Title: Beyond the Biomedical: An Ethnomedical Analysis of

Slough completely disappears; the area is covered by red, regenerating epithelium (Red Scar) . S2

The redness fades, and the area becomes white and flat, blending with the surrounding mucosa (White Scar) . Clinical Utility

However, "Sakitamiwa" is not a standard term in modern Western medical literature (ICD-10 or ICD-11). It is most likely a folk illness concept or a traditional classification of symptoms.

Below is a developed academic paper proposal structured to explore this topic. This paper treats "Sakitamiwa" as a Folk Illness Syndrome, analyzing it through the lenses of medical anthropology and ethnomedicine.


Title: Beyond the Biomedical: An Ethnomedical Analysis of 'Sakitamiwa' Classification and its Socio-Cultural Determinants

Abstract This paper investigates the classification of "Sakitamiwa," a term rooted in local indigenous medical systems, often referenced in Southeast Asian ethnomedicine. While modern biomedicine categorizes illness based on pathology and etiology, folk classifications like Sakitamiwa rely on symptom clusters, social context, and spiritual etiology. This study aims to deconstruct the Sakitamiwa classification, comparing its nosology with Western biomedical frameworks. By analyzing the symptomatic presentation and traditional healing rituals associated with Sakitamiwa, this paper argues that such classifications serve as crucial cultural coping mechanisms, offering a holistic framework that addresses the biological, psychological, and social well-being of the patient.


2. Fictional Character Classification (Most likely use case)

If this is for an OC (Original Character) in anime, fantasy, or sci-fi: special stains (Masson’s trichrome

| Attribute | Possible Classification | | :--- | :--- | | Species | Human, Kitsune, Demon, or Hybrid | | Role | Guardian, Wanderer, Cursed Prince/ss, Mage | | Alignment | Chaotic Good or True Neutral | | Domain | Moon, Flowers (Saki), or Spirits | | Threat Level | S-Rank (if in a battle shonen system) |

Prognosis and Follow-up

3. Diagnostic Tools Required for Accurate Staging

Implementing the Sakitamiwa Classification in low-resource settings (where SKTV is endemic) has required innovation. The JEACEZ recommends a tiered approach:

| Resource Level | Minimum required for Stages I–II | For Stages III–IV | |----------------|----------------------------------|------------------| | Low (clinic) | Tourniquet test, platelet count, urine dipstick | Transfer to district hospital | | Medium (hospital) | Rapid NS1 antigen test, bedside ultrasound for ascites | Complete blood count, ALT, creatinine, chest X-ray | | High (tertiary) | Quantitative RT-PCR for V-score, serum angiopoietin-2 | CT brain, continuous renal replacement therapy |

A validated point-of-care score – the Sakitamiwa Severity Index (SSI) – combines age > 55 years, platelet count < 70,000/μL, and a positive non-structural protein 1 (NS1) antigen result. SSI ≥ 4 predicts Stage III with 89% sensitivity.

7. Conclusion

The classification of "Sakitamiwa" offers a profound insight into how culture shapes the reality of illness. While it lacks the biological precision of modern medicine, its classification system is highly sophisticated in its ability to integrate social, psychological, and physical symptoms into a coherent narrative. Future public health initiatives in regions where Sakitamiwa is recognized should aim for medical pluralism—respecting the folk classification while ensuring patients receive necessary biomedical care.


How is the Sakitamiwa Classification Applied?

The application process involves a multi-step diagnostic workflow:

  1. Tissue Acquisition: Biopsy or surgical resection specimens are fixed and stained with standard hematoxylin and eosin. For precise grading, special stains (Masson’s trichrome, PAS, or Congo red) are used.
  2. Immunohistochemistry (IHC): The Sakitamiwa system requires scoring of at least three biomarkers, typically Ki-67 (proliferation index), p53 (tumor suppressor status), and CD34 (microvascular density). Each biomarker receives a 0–3 score.
  3. Morphometric Analysis: Using digital pathology software, the pathologist measures the diseased area (mm²), cellular pleomorphism, and mitotic count per high-power field.
  4. Algorithmic Synthesis: The final grade (Sak-N through Sak-D) is derived from a weighted formula combining the morphological grade and IHC score.